From molecules to medicine, from proteomics to prevention, the journals of the AACR cover the entire spectrum of cancer research. Please select the journal that is most appropriate for your manuscript ...

1Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon. 2Division of Hematology/Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon. ...

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. Accept ...

Inavolisib (Itovebi; Genentech) boosted survival in patients with HR-positive, HER2-negative advanced breast cancer and extended the time they could wait before starting chemotherapy. In the phase III ...

Findings from a multinational study suggest that adding an AI-integrated platform to training masterclasses for pathologists boosts their accuracy in classifying HER2-stained breast cancer samples, ...

Treatment with lurbinectedin (Zepzelca; Jazz Pharmaceuticals) and atezolizumab (Tecentriq; Genentech) improved overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC) ...

1Department of Biostatistics and Data Science, The University of Texas Health Science Center, Houston, Texas. 2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, ...

Major Finding: An inflammatory signature is a prognostic biomarker for CAR T-cell failure in non-Hodgkin lymphoma. Concept: InflaMix uses results from common blood tests to predict survival and ...

1Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, Massachusetts. 2Massachusetts Eye and Ear, Boston, Massachusetts.

Researchers found a treatable mechanism behind the cognitive problems that can follow CAR T-cell therapy, tracing them to overactive immune cells in the brain’s white matter. In mouse models, ...

Verastem’s avutometinib/defactinib combination earned FDA approval for KRAS-mutated low-grade serous ovarian cancer, marking the first treatment specifically for ...

Pfizer will acquire SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, from the Chinese biopharmaceutical company 3SBio for $1.25 billion upfront and $4.8 billion more for meeting certain ...